Zomedica Corp. · OTC:ZOMDF
Zomedica — NIBA Conference September 2022
16 slides from Zomedica's conference presentation, September 2022
Slide 1: “It’s All In The Waves”
WN <> ZOMEDICA “It’s All In The Waves” Larry Heaton Chief Executive Officer ZOM LISTED NYSE AMERICAN 9/30/2022
Slide 2: Forward Looking Statements
Forward Looking Statements These materials have been prepared for informational purposes only in relation to Zomedica and are not, under any circumstances, to be construed as an offering of any securities for sale directly or indirectly in any province or territory of Canada, in the United States or
Slide 3: Zomedica Investment Highlights
Zomedica • Animal health market $88.6 Investment Experienced, Large Growing Markets in billion by 2028(1) • Diagnostics to reach $12.6 Highlights Diagnostics & billion by 2026 Focused Therapeutics Management Team Low Cash Burn Cash on Hand $8M 1H22 $187M (6/30/22) Pathway to Profitability Gross Marg
Slide 4: Veteran Management Team with Decades of Experience
Veteran Management Team with Decades of Experience Larry Heaton Ann Cotter Tony Blair Karen DeHaan-Fullerton CEO CFO COO Chief Counsel & Corporate Secretary 35+ Years of 25+ Years of 30+ Years of 20+ Years of Experience Experience Experience Experience Adrian Lock Greg Blair Nicole Westfall VP Gener
Slide 5: Zomedica Critical Focus Areas
Zomedica Critical Focus Areas PulseVet® Shock Wave System Clinically Proven Global Leader TRUFORMA® Reference Lab Accuracy with Point of Care Convenience Expand Equine Indications Drive assay utilization Launch into for use to grow utilization Expand installed small animal Expand assay offerings bas
Slide 6: Diverse Go To Market Strategy
Diverse Go To Market Strategy Field Sales Reps Email Marketing Inside Sales Reps Public Relations Professional Services Veterinarians Custom Marketing and SEO Event and Conference Sales Web and Social Media International Sales Distributers Print and Catalog Ads Unified Multi- Marketing Ecommerce Dir
Slide 7: Global Sales Footprint
Global Sales Footprint UXR MedEquus Western Drug Distribution Center _(UK, Belgium, Luxembourg, Denmark, Sweden, Norway) Holistic Veterinary Solutions : . a (Canadc) E Companion Consultancy PulseVet Europe (UK) (Switzerland —Consultant) DAME IC VE DISTIC LTD STI MWI Veterinary Supply Co. MaRS) 7 (Tu
Slide 8: Substantial Year-Over-Year Revenue Growth
Substantial Year-Over-Year Revenue Growth Diagnostics net revenue (United Stated dollars in thousands) Therapeutics net revenue (United Stated dollars in thousands) $200 $10,000 $175 $9,000 +41% +398% $8,000 $150 $7,000 $125 $6,000 $100 $5,000 $4,000 $7,849 $75 $148 $3,000 $5,552 $50 $2,000 $25 $1,0
Slide 9: Zomedica Commercial Launch Cadence
Zomedica Commercial Launch Cadence 1H21 2H2021 1H2022 2H2022 1H2023 2H2023 TRUFORMATSH/TT4/Cortisol TRUFORMAeACTH TRUFORMAfT4 TRUFORMAGI Assays PulseVetproducts Assisiproducts SMPVetGuardian Revo2 SonoView Revo2 MicroView
Slide 10: Zomedica Critical Focus Areas
Zomedica Critical Focus Areas PulseVet® Shock Wave System Clinically Proven Global Leader TRUFORMA® Reference Lab Accuracy with Point of Care Convenience Expand Equine Indications Drive assay utilization Launch into for use to grow utilization Expand installed small animal Expand assay offerings bas
Slide 11: US Total Addressable Market $2.9B
US Total Addressable Market PulseVet Recurring Revenue $600 - $19,600 per year 30,000 Small Animal $2.9B TRUFORMA MicroView & 4450 Equine Capital Revenue Practices(2) 3,500- 30,000 Vet Per unit(1) Assisi Guardian (1) TRUFORMA through the CAP program is currently available for no up-front investment.
Slide 12: Business Development Opportunities
Business Development Opportunities Adding to Strong Product Portfolio Accelerating Balance Sheet • PulseVet shock wave therapy Innovation • $187 million cash position as • VetGuardian wireless • Industry innovation accelerating of 6/30/2022 [less $24 million remote monitoring but commercialization i
Slide 13: Financial Foundation & Performance
Financial Foundation & Performance 2022 Balance Sheet as of 6/30/2022 Second Quarter 2022 Profit & Loss Statement ($ 000's) 3 months 6 months Cash and Cash Equivalents 186,763 Revenue 4,246 7,997 Other Current Assets 10,863 Cost of Revenue 1,210 2,199 Gross Profit 3,036 5,798 Total Current Assets 19
Slide 14: Why Invest In Zomedica?
Why Invest In Zomedica? TRUFORMA® provides revolutionary Increasing revenues and attractive PulseVet® continues to grow equine reference lab accuracy with point of care gross margins provide pathway to business both in the US and internationally convenience. Continued investment in assay profitabili
Slide 15: “It’s All In The Waves”
— Investor Relations Contact: —Kirin Smith, President PCG Advisory Inc 646-823-8656 | ksmith@pcgadvisory.com 9/30/2022 <> ZOMEDICA “It’s All In The Waves” ZOM SKSHAEID) NYSE AMERICAN
Slide 16: Appendix - Endnotes
Appendix - Endnotes (1) JP Morgan coverage initiation report on Idexx and Heska, January 2021 (2) JP Morgan AH Industry overview Jan 2021 (3) Credit Suisse Animal Health Industry Primer, June 2021 Pg 16 Grandview Research August 2021 Global Market Insights 2016 pet owner survey conducted by The Huma